How do we treat fetal and neonatal alloimmune thrombocytopenia?

Transfusion

Volumn 54, Issue 7, 2014, Pages 1698-1703

  Bertrand, Gérald ^a   Kaplan, Cécile ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ALLOIMMUNIZATION; ANTIBODY BLOOD LEVEL; ARTICLE; BRAIN HEMORRHAGE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FOLLOW UP; HIGH RISK PREGNANCY; HUMAN; LABORATORY DIAGNOSIS; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NON INVASIVE PROCEDURE; PREGNANCY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPOIESIS;

ADRENAL CORTEX HORMONES; COST-BENEFIT ANALYSIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FETAL DISEASES; HUMANS; INFANT, NEWBORN; PARITY; PLATELET TRANSFUSION; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRENATAL CARE; PRENATAL DIAGNOSIS; PROGNOSIS; SEROLOGIC TESTS; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84904460995     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12671     Document Type: Article

References (43)

1. Dreyfus M, Kaplan C, Verdy E, et al.; Immune Thrombocytopenia Working Group. Frequency of immune thrombocytopenia in newborns: a prospective study. Blood 1997; 89: 4402-4406.
2. Metcalfe P, Watkins NA, Ouwehand WH, et al. Nomenclature of human platelet antigens. Vox Sang 2003; 85: 240-245.
3. Kumpel BM, Sibley K, Jackson DJ, et al. Ultrastructural localization of glycoprotein IIIa (GP IIIa, beta 3 integrin) on placental syncytiotrophoblast microvilli: implications for platelet alloimmunization during pregnancy. Transfusion 2008; 48: 2077-2086.
4. Kaplan C, Daffos F, Forestier F, et al. Current trends in neonatal alloimmune thrombocytopenia diagnosis and therapy. In:, Kaplan-Gouet C, Schlegel N, Salmon C, et al., editors. Platelet immunology: fundamental and clinical aspects. Paris: John Libbey-Eurotex/ed.INSERM; 1991. p. 267-278.
5. Bussel JB, Zacharoulis S, Kramer K, et al. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 2005; 45: 176-183.
6. Spencer JA, Burrows RF,. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 2001; 41: 45-55.
7. Valentin N, Vergracht A, Bignon JD, et al. HLA DRw52a and RFLP-subtyping in mothers alloimmunized against PlA1 platelet antigen. Hum Immunol 1989; 58: 2-16.
8. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989; 1: 363-366.
9. a) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 1991; 78: 425-429.
10. Glade-Bender J, McFarland JG, Kaplan C, et al. Anti-HPA-3a induces severe neonatal alloimmune thrombocytopenia. J Pediatr 2001; 138: 862-867.
11. Feng ML, Liu DZ, Shen W, et al. Establishment of an HPA-1- to -16-typed platelet donor registry in China. Transfus Med 2006; 16: 369-374.
12. a) feto-maternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy, report on 8 families. Transfusion 2005; 45: 1799-1803.
13. Bertrand G, Bianchi F, Alexandre M, et al. HPA-13bw neonatal alloimmune thrombocytopenia and low frequency alloantigens: case report and review of the literature. Transfusion 2007; 47: 1510-1513.
14. Bertrand G, Bianchi F, Quesne J, et al. A severe case of neonatal thrombocytopenia with a fatal outcome, implicating HPA-12bw fetomaternal platelet alloimmunization. Transfusion 2013; 53: 466-468.
15. Kiefel V, Santoso S, Weisheit M, et al. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70: 1722-1726.
16. Boehlen F, Bulla O, de Moerloose P,. Evaluation of a new antigen capture Elisa for detection and characterization of platelet alloantibodies. Thromb Res 1998; 92: 27-32.
17. Bertrand G, Kaplan C,. Fetal/neonatal alloimmune thrombocytopenia: recommendations for laboratory investigations. AABB News 2011; 13: 4-6.
18. Bakchoul T, Bertrand G, Krautwurst A, et al. The implementation of surface plasmon resonance technique in monitoring pregnancies with expected fetal and neonatal alloimmune thrombocytopenia. Transfusion 2013; 53: 2078-2085.
19. Peterson JA, Kanack A, Nayak D, et al. Prevalence and clinical significance of low-avidity HPA-1a antibodies in women exposed to HPA-1a during pregnancy. Transfusion 2012; 53: 1309-1318.
20. Allen DL, Samol J, Benjamin S, et al. Survey of the use and clinical effectiveness of HPA-1a/5b-negative platelet concentrates in proven or suspected platelet alloimmunization. Transfus Med 2004; 14: 409-417.
21. Lee K, Beaujean F, Bierling P,. Treatment of severe fetomaternal alloimmune thrombocytopenia with compatible frozen-thawed platelet concentrates. Br J Haematol 2002; 117: 482-483.
22. Kiefel V, Bassler D, Kroll H, et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 2006; 107: 3761-3763.
23. Bakchoul T, Bassler D, Heckmann M, et al. Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin. Transfusion 2014; 54: 640-645.
24. Daffos F, Forestier F, Muller JY, et al. Prenatal treatment of alloimmune thrombocytopenia. Lancet 1984; II: 632.
25. Kaplan C, Daffos F, Forestier F, et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood 1988; 72: 340-343.
26. Bussel JB, Berkowitz RL, McFarland JG, et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988; 319: 1374-1378.
27. Le Toriellec E, Chenet C, Kaplan C,. Safe fetal platelet genotyping: new developments. Transfusion 2013; 53: 1755-1762.
28. Paidas MJ, Berkowitz RL, Lynch L, et al. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995; 172: 475-479.
29. Bussel JB, Berkowitz RL, Hung C, et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol 2012; 203: 135.e1-14.
30. Bertrand G, Drame M, Martageix C, et al. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia. Blood 2011; 117: 3209-3213.
31. Cheryl A, Vinograd A, Bussel JB,. Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. Haematologica 2013; 95: 1807-1811.
32. Radder CM, de Hann MJ, Brand A, et al. Follow up of children after antenatal treatment for alloimmune thrombocytopenia. Early Hum Dev 2004; 80: 65-76.
33. Bertrand G, Martageix C, Jallu V, et al. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost 2006; 4: 628-637.
34. Killie MK, Kjeldsen-Kragh J, Husebekk A, et al. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 2007; 114: 588-595.
35. Durand-Zaleski I, Schlegel N, Blum-Boisgard C, et al.; the "Immune Thrombocytopenia" Working Group. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Am J Perinatol 1996; 13: 423-431.
36. Loewenthal R, Rosenberg N, Kalt R, et al. Compound heterozygosity of HLA-DRB3*01:01 and HLA-DRB4*01:01 as a potential predictor of fetal neonatal alloimmune thrombocytopenia. Transfusion 2013; 53: 344-352.
37. Hayashi T, Amakishi E, Matsuyama N, et al. Establishment of a cell line panel as an alternative source of platelet antigens for a screening assay of anti-human platelet antibodies. Transfus Med 2011; 21: 199-204.
38. Li C, Piran S, Chen P, et al. Maternal immune response to fetal platelet GPIba causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 2011; 121: 4537-4547.
39. Psaila B, Bussel JB,. Fc receptors in immune thrombocytopenia: a target for immunomodulation? J Clin Invest 2013; 118: 2677-2681.
40. Ghevaert C, Herbert N, Hawkins L, et al. Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers. Blood 2013; 122: 313-320.
41. Kjeldsen-Kragh J, Ni H, Skogen B,. Towards a prophylactic treatment of HPA-related foetal and neonatal alloimmune thrombocytopenia. Curr Opin Hematol 2012; 19: 469-474.
42. Tiller H, Killie MK, Chen P, et al. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion 2012; 52: 1446-1457.
43. Harrington WJ, Sprague CC, Minnich V, et al. Immunologic mechanisms in neonatal and thrombocytopenic purpura. Ann Intern Med 1953; 38: 433-469.